1. 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. (9th November 2020) Authors: Barlesi, Fabrice; Lolkema, Martijn; Rohrberg, Kristoffer Staal; Hierro, Cinta; Marabelle, Aurelien; Razak, Albiruni Abdul; Teixeira, Luis; Boni, Valentina; Miller, Wilson H; Aggarwal, Charu; Stern, Martin; Cirovic, Olivera; Cirovic, Olivera; Romagnoli, Barbara; Christen, Randolph; Dodia, Raksha; ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Inhibition of capsaicin‐driven nasal hyper‐reactivity by SB‐705498, a TRPV1 antagonist. (May 2014) Authors: Holland, Carlijn; van, Cornelis; Denyer, Jane; Smart, Kevin; Segboer, Christine; Terreehorst, Ingrid; Newlands, Amy; Beerahee, Misba; Fokkens, Wytske; Tsitoura, Daphne C. Journal: British journal of clinical pharmacology Issue: Volume 77:Number 5(2014:May) Page Start: 777 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor. Issue 3 (24th July 2020) Authors: Smart, Kevin; Bröske, Ann‐Marie; Rüttinger, Dominik; Mueller, Claudia; Phipps, Alex; Walz, Antje‐Christine; Ries, Carola; Baehner, Monika; Cannarile, Michael; Meneses‐Lorente, Georgina Journal: Clinical pharmacology & therapeutics Issue: Volume 108:Issue 3(2020) Page Start: 616 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗